Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience

Tools
- Tools
+ Tools

Sriskandarajah, P., Pawlyn, C., Mohammed, K., Dearden, C. E., Davies, F. E., Morgan, G. J., Boyd, K. D., Kaiser, M. F. (2017) The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. LEUKEMIA & LYMPHOMA, 58 (2). pp. 494-497. ISSN 1042-8194

Full text not available from this repository.

Item Type: Letter
Authors (ICR Faculty only): Morgan, Gareth and Davies, Faith
All Authors: Sriskandarajah, P., Pawlyn, C., Mohammed, K., Dearden, C. E., Davies, F. E., Morgan, G. J., Boyd, K. D., Kaiser, M. F.
Additional Information: ISI Document Delivery No.: ED1JH Times Cited: 0 Cited Reference Count: 14 Sriskandarajah, Priya Pawlyn, Charlotte Mohammed, Kabir Dearden, Claire E. Davies, Faith E. Morgan, Gareth J. Boyd, Kevin D. Kaiser, Martin F. 0 TAYLOR & FRANCIS LTD ABINGDON LEUKEMIA LYMPHOMA
Uncontrolled Keywords: REFRACTORY MULTIPLE-MYELOMA LOW-DOSE DEXAMETHASONE SURVIVAL BORTEZOMIB TRIAL IMIDS
Research teams: ICR divisions > Clinical Studies > Molecular Haematology (including Cytogenetics Group and Cell Markers)
ICR divisions > Molecular Pathology > Molecular Haematology (including Cytogenetics Group and Cell Markers)

Closed research groups > Myeloma Targeted Treatment
Depositing User: Barry Jenkins
Date Deposited: 05 Jan 2017 12:05
Last Modified: 05 Jan 2017 12:05
URI: http://publications.icr.ac.uk/id/eprint/15535

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust